The Impact of an Antimicrobial Stewardship Program on Days of Therapy in the Pediatric Center: An Interrupted Time-Series Analysis of a 19-Year Study.

IF 3 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Journal of Korean Medical Science Pub Date : 2024-06-03 DOI:10.3346/jkms.2024.39.e172
Kyung-Ran Kim, Hyo Jung Park, Sun-Young Baek, Soo-Han Choi, Byung-Kee Lee, SooJin Kim, Jong Min Kim, Ji-Man Kang, Sun-Ja Kim, Sae Rom Choi, Dongsub Kim, Joon-Sik Choi, Yoonsun Yoon, Hwanhee Park, Doo Ri Kim, Areum Shin, Seonwoo Kim, Yae-Jean Kim
{"title":"The Impact of an Antimicrobial Stewardship Program on Days of Therapy in the Pediatric Center: An Interrupted Time-Series Analysis of a 19-Year Study.","authors":"Kyung-Ran Kim, Hyo Jung Park, Sun-Young Baek, Soo-Han Choi, Byung-Kee Lee, SooJin Kim, Jong Min Kim, Ji-Man Kang, Sun-Ja Kim, Sae Rom Choi, Dongsub Kim, Joon-Sik Choi, Yoonsun Yoon, Hwanhee Park, Doo Ri Kim, Areum Shin, Seonwoo Kim, Yae-Jean Kim","doi":"10.3346/jkms.2024.39.e172","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We aimed to analyze the effects of an antimicrobial stewardship program (ASP) on the proportion of antimicrobial-resistant pathogens in bacteremia, antimicrobial use, and mortality in pediatric patients.</p><p><strong>Methods: </strong>A retrospective single-center study was performed on pediatric inpatients under 19 years old who received systemic antimicrobial treatment from 2001 to 2019. A pediatric infectious disease attending physician started ASP in January 2008. The study period was divided into the pre-intervention (2001-2008) and the post-intervention (2009-2019) periods. The amount of antimicrobial use was defined as days of therapy per 1,000 patient-days, and the differences were compared using delta slope (= changes in slopes) between the two study periods by an interrupted time-series analysis. The proportion of resistant pathogens and the 30-day overall mortality rate were analyzed by the χ².</p><p><strong>Results: </strong>The proportion of extended-spectrum beta-lactamase (ESBL)-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> bacteremia increased from 17% (39 of 235) in the pre-intervention period to 35% (189 of 533) in the post-intervention period (<i>P</i> < 0.001). The total amount of antimicrobial use significantly decreased after the introduction of ASP (delta slope value = -16.5; 95% confidence interval [CI], -30.6 to -2.3; <i>P</i> = 0.049). The 30-day overall mortality rate in patients with bacteremia did not increase, being 10% (55 of 564) in the pre-intervention and 10% (94 of 941) in the post-intervention period (<i>P</i> = 0.881).</p><p><strong>Conclusion: </strong>The introduction of ASP for pediatric patients reduced the delta slope of the total antimicrobial use without increasing the mortality rate despite an increased incidence of ESBL-producing gram-negative bacteremia.</p>","PeriodicalId":16249,"journal":{"name":"Journal of Korean Medical Science","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11147790/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Korean Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3346/jkms.2024.39.e172","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: We aimed to analyze the effects of an antimicrobial stewardship program (ASP) on the proportion of antimicrobial-resistant pathogens in bacteremia, antimicrobial use, and mortality in pediatric patients.

Methods: A retrospective single-center study was performed on pediatric inpatients under 19 years old who received systemic antimicrobial treatment from 2001 to 2019. A pediatric infectious disease attending physician started ASP in January 2008. The study period was divided into the pre-intervention (2001-2008) and the post-intervention (2009-2019) periods. The amount of antimicrobial use was defined as days of therapy per 1,000 patient-days, and the differences were compared using delta slope (= changes in slopes) between the two study periods by an interrupted time-series analysis. The proportion of resistant pathogens and the 30-day overall mortality rate were analyzed by the χ².

Results: The proportion of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia increased from 17% (39 of 235) in the pre-intervention period to 35% (189 of 533) in the post-intervention period (P < 0.001). The total amount of antimicrobial use significantly decreased after the introduction of ASP (delta slope value = -16.5; 95% confidence interval [CI], -30.6 to -2.3; P = 0.049). The 30-day overall mortality rate in patients with bacteremia did not increase, being 10% (55 of 564) in the pre-intervention and 10% (94 of 941) in the post-intervention period (P = 0.881).

Conclusion: The introduction of ASP for pediatric patients reduced the delta slope of the total antimicrobial use without increasing the mortality rate despite an increased incidence of ESBL-producing gram-negative bacteremia.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
抗菌药物管理计划对儿科中心治疗天数的影响:19年研究的间断时间序列分析。
背景:我们旨在分析抗菌药物管理计划(ASP)对儿科患者菌血症中耐药病原体比例、抗菌药物使用和死亡率的影响:对2001年至2019年期间接受全身抗菌治疗的19岁以下儿科住院患者进行了一项回顾性单中心研究。一名儿科传染病主治医师于 2008 年 1 月启动了 ASP。研究期间分为干预前(2001-2008 年)和干预后(2009-2019 年)。抗菌药物使用量定义为每 1,000 个患者日中的治疗天数,通过间断时间序列分析,使用 delta 坡度(= 坡度变化)比较两个研究期间的差异。耐药病原体的比例和30天总死亡率用χ²进行分析:结果:产生广谱β-内酰胺酶(ESBL)的大肠埃希菌和肺炎克雷伯菌菌血症的比例从干预前的 17%(235 例中的 39 例)增加到干预后的 35%(533 例中的 189 例)(P < 0.001)。引入 ASP 后,抗菌药物使用总量显著下降(delta 斜坡值 = -16.5;95% 置信区间 [CI],-30.6 至 -2.3;P = 0.049)。菌血症患者的 30 天总死亡率没有增加,干预前为 10%(564 例中的 55 例),干预后为 10%(941 例中的 94 例)(P = 0.881):结论:尽管产ESBL革兰氏阴性菌血症的发生率有所上升,但对儿科患者采用ASP减少了抗菌药物总使用量的delta斜率,而死亡率却没有增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Korean Medical Science
Journal of Korean Medical Science 医学-医学:内科
CiteScore
7.80
自引率
8.90%
发文量
320
审稿时长
3-6 weeks
期刊介绍: The Journal of Korean Medical Science (JKMS) is an international, peer-reviewed Open Access journal of medicine published weekly in English. The Journal’s publisher is the Korean Academy of Medical Sciences (KAMS), Korean Medical Association (KMA). JKMS aims to publish evidence-based, scientific research articles from various disciplines of the medical sciences. The Journal welcomes articles of general interest to medical researchers especially when they contain original information. Articles on the clinical evaluation of drugs and other therapies, epidemiologic studies of the general population, studies on pathogenic organisms and toxic materials, and the toxicities and adverse effects of therapeutics are welcome.
期刊最新文献
Effectiveness of the Bivalent mRNA COVID-19 Vaccine for Preventing Critical Infection From the SARS-CoV-2 Omicron Variant in the Republic of Korea. LETter To the EditoR Standards (LETTERS): Considerations for Authors, Reviewers, and Editors. Modified Albumin-Bilirubin Grade After Curative Treatment: Predicting the Risk of Late Intrahepatic Recurrence of Hepatocellular Carcinoma. Validity of the Tablet-Based Digital Cognitive Test (SCST) in Identifying Different Degrees of Cognitive Impairment. Diagnostic Utility of Whole Genome Sequencing After Negative Karyotyping/Chromosomal Microarray in Infants Born With Multiple Congenital Anomalies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1